Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-drug interaction study of OP-2024 with Rabeprazole or Magnesium Oxide in healthy male volunteers
jRCT2031250158Phase 1Completed
- Sponsor
- Ohara Pharmaceutical Co., Ltd.
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of XI Ning in Parkinson's disease (PD) (3 arms), sponsored by Ohara Pharmaceutical Co., Ltd. Primary endpoint: Pharmacokinetics of OP-2024. Started Jun 2025; status: completed.
02
Drugs
XI Ning
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2031250158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250158.